BioWorld

June 23, 2004

View Archived Issues

Vertex, Merck Form Potential $384M Cancer Deal For VX-680

In a deal potentially worth $384 million for Vertex Pharmaceuticals Inc., the company entered a global collaboration with Merck & Co. Inc. to develop and commercialize the former's lead aurora kinase inhibitor, VX-680. (BioWorld Today) Read More

Merix, Kirin Collaborating For Personalized Vaccine Products

Read More

CuraGen, Seattle Genetics Form Cancer Deal Worth Up To $32M

Read More

Momenta's Stock Closes Up After IPO Brings In $34.7M

Read More

Taste Technology Firm Senomyx Goes Public With $36M Offering

Read More

Other News To Note

Read More